logo
Pray for Us Zynners

Pray for Us Zynners

Yahoo05-03-2025

New York politicians are again targeting the finance sector—this time with a proposed ban on flavored nicotine pouches.
The proposal, sponsored by state Sen. Brad Hoylman-Sigal (D–Manhattan), follows a one-two punch from Democratic Gov. Kathy Hochul to bar private equity from real estate investments and to outlaw "buy now, pay later" options on internet purchases.
Nicotine pouches (including ZYN, Sesh, and Excel) deliver a buzz that keeps minds sharp and margins strong. Those in the know attest to the unparalleled edge that nicotine pouches provide. They help you lock in when you need it most: generating slide decks for client meetings, running models for your managing director, or pretending to understand what your quant just pulled from the terminal.
Jokes aside, this proposal would be bad public health policy.
Nicotine pouches—almond-sized packets users place between the lip and the gums—are an alternative to cigarettes and other harmful tobacco products. They contain a derived version of the nicotine compound that tobacco users crave without the carcinogenic sluff that comes with cigarettes and smokeless tobacco.
Cigarettes, still popular despite declining smoking rates, are high-risk. Cigarette smoke contains at least 70 known carcinogens, including benzene and arsenic. Smokeless tobacco—chew and dip—doesn't burn, but it still contains 28 known carcinogens, dramatically increasing the risk of oral, esophageal, and pancreatic cancers.
Nicotine pouches contain no tobacco leaf and no known carcinogens. They just deliver nicotine—potentially addictive, yes, but not known to be inherently harmful. Indeed, they are harm reducers, giving people who want the concentration and mood benefits of the compound an option that avoids the grave risks more traditional products pose. Last year a randomized controlled trial in the journal Nicotine & Tobacco Research concluded that pouches "show the potential" of alternative nicotine delivery systems in helping smokers kick the habit. Viewed in that context, the trebling of pouch sales in New York state since 2022 is good news.
Recognizing the positive tradeoffs, the U.S. Food and Drug Administration (FDA) granted ZYN authorization in January to market its flavored pouches nationally under its premarket tobacco product application pathway "following an extensive scientific review." According to the FDA, these products met the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act, which "considers the risks and benefits of products to the population as a whole."
Hoylman-Sigal argues that kids will see pouches as glamorous, but there's no good evidence of that. Among American middle and high school students, tobacco use continues on a downward trend. From 2023 to 2024, the Centers for Disease Control and Prevention reports that use of any tobacco product in that age group fell from 13 percent to 10 percent. Less than 2 percent used pouches.
And as with all banned substances, outlawing flavored nicotine pouches will spark a black market and create a whole new kind of derivative trading. Unless Hoylman-Sigal wants a network of finance interns smuggling arbitraged wintergreen on the PATH train from Jersey City, they ought to can this ban.
The post Pray for Us Zynners appeared first on Reason.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The $7 Billion Nicotine-Pouch Market's Next Target? Women
The $7 Billion Nicotine-Pouch Market's Next Target? Women

Bloomberg

time3 hours ago

  • Bloomberg

The $7 Billion Nicotine-Pouch Market's Next Target? Women

At Odenplan Square in central Stockholm, high school students move in packs, enjoying a day off and the early spring weather. Even though graduation is still weeks away, some seniors are already sporting their celebratory caps, per Swedish tradition. One of them is 19-year-old Olivia Persson, who, in addition to wearing the sailor-style hat, carries a bright tin of nicotine pouches. So do most of the other girls in her crew, each in turn showing off colorful containers with peach and apple-mint flavors tucked into pockets and purses. 'It's just fun,' Persson says of the Chiclet-size packets, or tobacco-free snus, that users tuck between their gums and lips for a quick hit of nicotine. 'You feel more alert, and everyone does it, so it's easy to think, 'How bad can it be?' '

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

Business Upturn

time4 hours ago

  • Business Upturn

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV VLP in children 2 to 11 years of age. This first trial of CHIKV VLP in a pediatric population aims to expand the target population for the vaccine, currently approved for persons 12 years of age and older in the US, EU and United Kingdom under the trade name VIMKUNYA®. The global, randomized, double-blind, placebo-controlled study (NCT07003984), sponsored by Bavarian Nordic, will evaluate the safety and immunogenicity of CHIK VLP vaccine in 720 children 2 to 11 years of age for two years. Primary results from the study are anticipated in the first half of 2028. Paul Chaplin, President & CEO of Bavarian Nordic, said: 'Upon the successful approvals earlier this year of our chikungunya vaccine for persons aged 12 and older, we are pleased to initiate this Phase 3 study in children for whom there are currently no vaccines available to prevent against chikungunya. This study represents a significant part of our commitment to the further development of the vaccine to help ensure access for people of all ages.' About VIMKUNYA® Chikungunya vaccine (recombinant, adsorbed) VIMKUNYA (CHIKV VLP) is the first and only virus-like particle (VLP) vaccine for the prevention of chikungunya disease in individuals aged 12 years and above. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. VIMKUNYA is the only single-dose vaccine against chikungunya disease available in a prefilled syringe. VIMKUNYA does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. The vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 20251,2 and the United Kingdom in May 20253. The US, EU and UK approvals of VIMKUNYA (CHIKV VLP vaccine) were all based on results from two phase 3 clinical trials which enrolled more than 3,500 healthy individuals 12 years of age and older. The studies met their primary endpoints, with results showing that 21 days after vaccination, the vaccine induced neutralizing antibodies in up to 97.8% of the vaccinated individuals, (97.8% in individuals 12 years to 64 and 87.3% in over 65-year-olds). The key secondary endpoint of seroresponse rate at day 8 post vaccination was 46.6% and 96.8% at day 15 in the 12–64-year-old population and 82.3% at day 15 for the over 65 population. The vaccine was well-tolerated and vaccine-related adverse events were mainly mild or moderate in nature. The most common side effects were pain at the injection site, fatigue, headache, and muscle pain4,5. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV). In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, CHIKV has been identified in more than 110 countries, with evidence of transmission confirmed in more than 50 countries over the past five years6. Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover within 1-2 weeks, but 30-40% of those affected may develop chronic arthritis that can last for months or even years7. In 2024, 620,000 cases of chikungunya and over 200 deaths were reported worldwide8. Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile9. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Rolf Sass Sørensen, Vice President Investor Relations, [email protected], Tel: +45 61 77 47 43 US: Graham Morrell, Paddock Circle Advisors, [email protected], Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03 1 Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older. 2 Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older. 3 Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom. 4 Richardson JS, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adolescents and Adults. medRxiv 2024.10.11.24315179. 5 Tindale LC, et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adults ≥65 Years of Age. medRxiv 2024.10.10.24315205. 6 Centers for Disease Control and Prevention. Areas at Risk for Chikungunya. 7 European Centre for Disease Prevention and Control. Chikungunya virus disease. 8 European Centre for Disease Prevention and Control. Chikungunya virus disease case notification rate per 100 000 population, January 2024-December 2024. 9 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/ PMID: 38711542; PMCID: PMC11070701. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store